vs

Side-by-side financial comparison of ONESPAWORLD HOLDINGS Ltd (OSW) and PHIBRO ANIMAL HEALTH CORP (PAHC). Click either name above to swap in a different company.

PHIBRO ANIMAL HEALTH CORP is the larger business by last-quarter revenue ($373.9M vs $242.1M, roughly 1.5× ONESPAWORLD HOLDINGS Ltd). PHIBRO ANIMAL HEALTH CORP runs the higher net margin — 7.3% vs 5.0%, a 2.4% gap on every dollar of revenue. On growth, PHIBRO ANIMAL HEALTH CORP posted the faster year-over-year revenue change (20.9% vs 11.5%). ONESPAWORLD HOLDINGS Ltd produced more free cash flow last quarter ($14.9M vs $8.3M). Over the past eight quarters, PHIBRO ANIMAL HEALTH CORP's revenue compounded faster (19.2% CAGR vs 7.1%).

Phibro Animal Health Corporation is an American animal health and mineral nutrition company. Its products include antibacterials, anticoccidials, anthelmintics, as well as animal nutrition and vaccines for livestock. The company operates through three segments Mineral Nutrition, Performance Materials, and Animal Health, from which most of its revenue is derived. The company operates in the United States, Latin America, Canada, Europe, Middle East, Africa, and Asia-Pacific. It is incorporated ...

OSW vs PAHC — Head-to-Head

Bigger by revenue
PAHC
PAHC
1.5× larger
PAHC
$373.9M
$242.1M
OSW
Growing faster (revenue YoY)
PAHC
PAHC
+9.4% gap
PAHC
20.9%
11.5%
OSW
Higher net margin
PAHC
PAHC
2.4% more per $
PAHC
7.3%
5.0%
OSW
More free cash flow
OSW
OSW
$6.7M more FCF
OSW
$14.9M
$8.3M
PAHC
Faster 2-yr revenue CAGR
PAHC
PAHC
Annualised
PAHC
19.2%
7.1%
OSW

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
OSW
OSW
PAHC
PAHC
Revenue
$242.1M
$373.9M
Net Profit
$12.1M
$27.5M
Gross Margin
35.5%
Operating Margin
6.8%
13.5%
Net Margin
5.0%
7.3%
Revenue YoY
11.5%
20.9%
Net Profit YoY
-16.2%
762.1%
EPS (diluted)
$0.12
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OSW
OSW
PAHC
PAHC
Q4 25
$242.1M
$373.9M
Q3 25
$258.5M
$363.9M
Q2 25
$240.7M
$378.7M
Q1 25
$219.6M
$347.8M
Q4 24
$217.2M
$309.3M
Q3 24
$241.7M
$260.4M
Q2 24
$224.9M
$273.2M
Q1 24
$211.2M
$263.2M
Net Profit
OSW
OSW
PAHC
PAHC
Q4 25
$12.1M
$27.5M
Q3 25
$24.3M
$26.5M
Q2 25
$19.9M
$17.2M
Q1 25
$15.3M
$20.9M
Q4 24
$14.4M
$3.2M
Q3 24
$21.6M
$7.0M
Q2 24
$15.8M
$752.0K
Q1 24
$21.2M
$8.4M
Gross Margin
OSW
OSW
PAHC
PAHC
Q4 25
35.5%
Q3 25
32.9%
Q2 25
29.0%
Q1 25
30.1%
Q4 24
32.9%
Q3 24
32.1%
Q2 24
31.9%
Q1 24
30.2%
Operating Margin
OSW
OSW
PAHC
PAHC
Q4 25
6.8%
13.5%
Q3 25
10.2%
14.1%
Q2 25
9.2%
8.9%
Q1 25
7.7%
9.6%
Q4 24
7.9%
8.3%
Q3 24
10.3%
6.8%
Q2 24
8.4%
6.7%
Q1 24
8.0%
7.6%
Net Margin
OSW
OSW
PAHC
PAHC
Q4 25
5.0%
7.3%
Q3 25
9.4%
7.3%
Q2 25
8.3%
4.5%
Q1 25
7.0%
6.0%
Q4 24
6.6%
1.0%
Q3 24
8.9%
2.7%
Q2 24
7.0%
0.3%
Q1 24
10.0%
3.2%
EPS (diluted)
OSW
OSW
PAHC
PAHC
Q4 25
$0.12
$0.67
Q3 25
$0.23
$0.65
Q2 25
$0.19
$0.43
Q1 25
$0.15
$0.51
Q4 24
$0.13
$0.08
Q3 24
$0.20
$0.17
Q2 24
$0.15
$0.02
Q1 24
$0.21
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OSW
OSW
PAHC
PAHC
Cash + ST InvestmentsLiquidity on hand
$16.3M
$74.5M
Total DebtLower is stronger
$84.0M
$624.2M
Stockholders' EquityBook value
$542.6M
$332.4M
Total Assets
$707.1M
$1.4B
Debt / EquityLower = less leverage
0.15×
1.88×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OSW
OSW
PAHC
PAHC
Q4 25
$16.3M
$74.5M
Q3 25
$29.6M
$85.3M
Q2 25
$35.0M
$77.0M
Q1 25
$22.6M
$70.4M
Q4 24
$57.4M
$67.1M
Q3 24
$48.8M
$89.8M
Q2 24
$62.5M
$114.6M
Q1 24
$65.4M
$98.7M
Total Debt
OSW
OSW
PAHC
PAHC
Q4 25
$84.0M
$624.2M
Q3 25
$85.2M
$628.0M
Q2 25
$96.2M
$631.7M
Q1 25
$97.4M
$635.4M
Q4 24
$98.6M
$639.1M
Q3 24
$98.7M
$295.2M
Q2 24
$123.8M
$312.1M
Q1 24
$138.6M
Stockholders' Equity
OSW
OSW
PAHC
PAHC
Q4 25
$542.6M
$332.4M
Q3 25
$552.8M
$311.7M
Q2 25
$548.3M
$285.7M
Q1 25
$530.6M
$266.0M
Q4 24
$554.5M
$246.8M
Q3 24
$540.1M
$258.5M
Q2 24
$532.7M
$256.6M
Q1 24
$515.5M
$270.1M
Total Assets
OSW
OSW
PAHC
PAHC
Q4 25
$707.1M
$1.4B
Q3 25
$732.6M
$1.4B
Q2 25
$731.8M
$1.4B
Q1 25
$708.7M
$1.3B
Q4 24
$746.4M
$1.3B
Q3 24
$734.0M
$966.3M
Q2 24
$756.8M
$982.2M
Q1 24
$763.6M
$979.0M
Debt / Equity
OSW
OSW
PAHC
PAHC
Q4 25
0.15×
1.88×
Q3 25
0.15×
2.01×
Q2 25
0.18×
2.21×
Q1 25
0.18×
2.39×
Q4 24
0.18×
2.59×
Q3 24
0.18×
1.14×
Q2 24
0.23×
1.22×
Q1 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OSW
OSW
PAHC
PAHC
Operating Cash FlowLast quarter
$20.0M
$19.4M
Free Cash FlowOCF − Capex
$14.9M
$8.3M
FCF MarginFCF / Revenue
6.2%
2.2%
Capex IntensityCapex / Revenue
2.1%
3.0%
Cash ConversionOCF / Net Profit
1.65×
0.70×
TTM Free Cash FlowTrailing 4 quarters
$68.4M
$47.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OSW
OSW
PAHC
PAHC
Q4 25
$20.0M
$19.4M
Q3 25
$33.2M
$9.3M
Q2 25
$20.3M
$21.3M
Q1 25
$10.1M
$43.2M
Q4 24
$16.6M
$3.1M
Q3 24
$28.6M
$12.6M
Q2 24
$18.7M
$28.4M
Q1 24
$15.0M
$11.4M
Free Cash Flow
OSW
OSW
PAHC
PAHC
Q4 25
$14.9M
$8.3M
Q3 25
$27.6M
$-4.5M
Q2 25
$17.6M
$8.1M
Q1 25
$8.4M
$35.4M
Q4 24
$13.2M
$-4.7M
Q3 24
$27.5M
$3.0M
Q2 24
$17.6M
$15.4M
Q1 24
$13.7M
$1.7M
FCF Margin
OSW
OSW
PAHC
PAHC
Q4 25
6.2%
2.2%
Q3 25
10.7%
-1.2%
Q2 25
7.3%
2.1%
Q1 25
3.8%
10.2%
Q4 24
6.1%
-1.5%
Q3 24
11.4%
1.2%
Q2 24
7.8%
5.6%
Q1 24
6.5%
0.6%
Capex Intensity
OSW
OSW
PAHC
PAHC
Q4 25
2.1%
3.0%
Q3 25
2.2%
3.8%
Q2 25
1.1%
3.5%
Q1 25
0.8%
2.2%
Q4 24
1.5%
2.5%
Q3 24
0.5%
3.7%
Q2 24
0.5%
4.8%
Q1 24
0.6%
3.7%
Cash Conversion
OSW
OSW
PAHC
PAHC
Q4 25
1.65×
0.70×
Q3 25
1.36×
0.35×
Q2 25
1.02×
1.24×
Q1 25
0.66×
2.07×
Q4 24
1.15×
0.97×
Q3 24
1.33×
1.81×
Q2 24
1.19×
37.80×
Q1 24
0.71×
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OSW
OSW

Services$197.3M82%
Products$44.8M18%

PAHC
PAHC

Medicated Feed Additives And Others$202.1M54%
Mineral Nutrition$68.9M18%
Nutritional Specialties$50.2M13%
Vaccines$37.6M10%
Performance Products$15.0M4%

Related Comparisons